Erasca ERAS Stock
Erasca Price Chart
Erasca ERAS Financial and Trading Overview
| Erasca stock price | 2.11 USD |
| Previous Close | 2.71 USD |
| Open | 2.7 USD |
| Bid | 0 USD x 2200 |
| Ask | 0 USD x 800 |
| Day's Range | 2.61 - 2.83 USD |
| 52 Week Range | 2.49 - 10.74 USD |
| Volume | 860.16K USD |
| Avg. Volume | 857.69K USD |
| Market Cap | 417.6M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.83 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.67 USD |
ERAS Valuation Measures
| Enterprise Value | 76.86M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.3083332 |
| PEG Ratio (5 yr expected) | 0.17 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.079922 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.531 |
Trading Information
Erasca Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -43.81% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 10.74 USD |
| 52 Week Low | 2.49 USD |
| 50-Day Moving Average | 2.86 USD |
| 200-Day Moving Average | 4.96 USD |
ERAS Share Statistics
| Avg. Volume (3 month) | 857.69K USD |
| Avg. Daily Volume (10-Days) | 798.84K USD |
| Shares Outstanding | 150.76M |
| Float | 84.76M |
| Short Ratio | 17.8 |
| % Held by Insiders | 21.75% |
| % Held by Institutions | 65.62% |
| Shares Short | 10.22M |
| Short % of Float | 9.47% |
| Short % of Shares Outstanding | 6.78% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -19.61% |
| Return on Equity (ttm) | -59.066% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -144838000 USD |
| Net Income Avi to Common (ttm) | -239546000 USD |
| Diluted EPS (ttm) | -1.77 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 389.74M USD |
| Total Cash Per Share (mrq) | 2.59 USD |
| Total Debt (mrq) | 58.06M USD |
| Total Debt/Equity (mrq) | 15.02 USD |
| Current Ratio (mrq) | 15.589 |
| Book Value Per Share (mrq) | 2.565 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -103816000 USD |
| Levered Free Cash Flow (ttm) | -91531248 USD |
Profile of Erasca
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 10835 Road to the Cure |
| ZIP | 92121 |
| Phone | 858 465 6511 |
| Website | https://www.erasca.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 129 |
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Q&A For Erasca Stock
What is a current ERAS stock price?
Erasca ERAS stock price today per share is 2.11 USD.
How to purchase Erasca stock?
You can buy ERAS shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Erasca?
The stock symbol or ticker of Erasca is ERAS.
Which industry does the Erasca company belong to?
The Erasca industry is Biotechnology.
How many shares does Erasca have in circulation?
The max supply of Erasca shares is 151.49M.
What is Erasca Price to Earnings Ratio (PE Ratio)?
Erasca PE Ratio is now.
What was Erasca earnings per share over the trailing 12 months (TTM)?
Erasca EPS is -0.83 USD over the trailing 12 months.
Which sector does the Erasca company belong to?
The Erasca sector is Healthcare.
Erasca ERAS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}